Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Pretty weak financial results growth rate 8.9% (average between last period year over year growth for revenue and EBITDA), there is slowdown compared to average historical growth rates (11.9%)
  • Dividend yield for the last twelve months 2.8%
  • Free cash flow yield -2.9% (LTM)
  • Share price is 27.1% higher than minimum and -0.2% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (14.6x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (+0.5%)180.61
year average price 158.83  


year start price 162.06 2024-09-30

min close price 142.06 2025-01-10

max close price 179.71 2025-09-26

current price 180.70 2025-09-29
Common stocks: 2 631 399 832

Dividend Yield:  2.8%
FCF Yield LTM: -2.9%
EV / LTM EBITDA: 14.6x
EV / EBITDA annualized: 15.0x
Last revenue growth (y/y):  +5.8%
Last growth of EBITDA (y/y):  +12.0%
Historical revenue growth:  +0.6%
Historical growth of EBITDA:  +23.3%
Target EV / EBITDA (hist percentile):
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 475 257
Net Debt ($m): 31 881
EV (Enterprise Value): 507 138
EBITDA LTM ($m): 34 804
EV / LTM EBITDA: 14.6x
Price to Book: 6.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-09-28fool.com

Why Johnson & Johnson Could Be the Ultimate Dividend King

2025-09-26youtube.com

'I'm an optimist,' says Johnson & Johnson CEO on its R&D investment

2025-09-26youtube.com

Watch Jim Cramer's interview with Johnson & Johnson CEO Joaquin Duato

2025-09-25zacks.com

Johnson & Johnson (JNJ) Could Be a Great Choice

2025-09-25fool.com

3 Exceptional High-Yielding Dividend Kings That Have Been Increasing Their Payouts for Over 60 Years

2025-09-24seekingalpha.com

Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

2025-09-23fool.com

The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now

2025-09-21fool.com

Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years?

2025-09-20fool.com

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill

2025-09-19prnewswire.com

TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data